Apr 7, 2025 | Press Releases
CULVER CITY, Calif., April 7, 2025 – ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the...
Mar 26, 2025 | Press Releases
CULVER CITY, Calif., March 25, 2025 – ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth...
Mar 13, 2025 | Press Releases
U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S. shortages and provide an alternative source of BCG, a critical...
Mar 3, 2025 | Press Releases
With a permanent J-code (J9028) awarded in January 2025, ImmunityBio’s February 2025 ANKTIVA® unit sales volume grew 97% over unit sales volume in December 2024 ANKTIVA sales momentum continues to trend upward quarter to date 2025, with sales volume in February...
Feb 27, 2025 | Press Releases
Regenerative Medicine Advanced Therapy (RMAT) designation follows clinical data of Absolute Lymphocyte Count (ALC) and significant Overall Survival (OS) correlations in QUILT trials across multiple tumor types including third line or greater metastatic pancreatic...
Feb 19, 2025 | Press Releases
Next-generation recombinant Bacillus Calmette-Guérin (rBCG) has undergone Phase 2 clinical trials in Europe in non-muscle invasive bladder cancer (NMIBC) Supplies of rBCG are now available, with shipments set to begin immediately via an FDA Expanded Access Program...
